Web Analytics

3 Latest Announced Rounds

  • $33,500,000
    Series B

    3 Investors

    Biotechnology Research
    Jan 14th, 2026
  • $1,863,303
    Pre-Seed

    2 Investors

    Software Development
    Jan 14th, 2026
  • $5,000,000
    Seed
    Pharmaceutical Manufacturing
    Jan 14th, 2026
$2,498.16M Raised in 48 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Indapta Therapeutics

start up
United States - Seattle & Houston
  • 18/12/2024
  • Unknown
  • $22,500,000

Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.


Related People

Mark FrohlichFounder

Mark Frohlich United States - Greater Seattle Area

N/A